Screener
Corcept Therapeutics CORT Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Preferred stock | — | — |
| Common stock | 142 | 140 |
| Treasury stock | (998,013) | (966,586) |
| Additional paid-in capital | 1,048,598 | 968,600 |
| Accumulated other comprehensive income | 436 | 2,264 |
| Retained earnings | 654,613 | 643,387 |
| Total stockholders’ equity | 705,776 | 647,805 |
| Total liabilities and stockholders’ equity | $888,702 | $836,651 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's retained earnings?
- Corcept Therapeutics (CORT) reported retained earnings of $654.61M in Q2 2026.
- How has Corcept Therapeutics's retained earnings changed year-over-year?
- Corcept Therapeutics's retained earnings increased by 9.2% year-over-year, from $599.43M to $654.61M.
- What is the long-term trend for Corcept Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Corcept Therapeutics's retained earnings has grown at a 50.8% compound annual growth rate (CAGR), from $82.46M to $643.39M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Corcept Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude